Kendall Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $351K | Hold |
2,295
| – | – | 0.07% | 180 |
|
|
2025
Q4 | $316K | Hold |
2,295
| – | – | 0.07% | 187 |
|
|
2025
Q3 | $294K | Sell |
2,295
-50
| -2% | -$6.1K | 0.07% | 194 |
|
|
2025
Q2 | $284K | Hold |
2,345
| – | – | 0.08% | 191 |
|
|
2025
Q1 | $261K | Hold |
2,345
| – | – | 0.08% | 193 |
|
|
2024
Q4 | $228K | Hold |
2,345
| – | – | 0.07% | 203 |
|
|
2024
Q3 | $270K | Hold |
2,345
| – | – | 0.08% | 192 |
|
|
2024
Q2 | $250K | Sell |
2,345
-76
| -3% | -$7.63K | 0.08% | 192 |
|
|
2024
Q1 | $234K | Buy |
2,421
+51
| +2% | +$5.23K | 0.08% | 196 |
|
|
2023
Q4 | $239K | Sell |
2,370
-100
| -4% | -$9.65K | 0.09% | 188 |
|
|
2023
Q3 | $252K | Hold |
2,470
| – | – | 0.11% | 174 |
|
|
2023
Q2 | $249K | Sell |
2,470
-300
| -11% | -$30K | 0.11% | 172 |
|
|
2023
Q1 | $255K | Sell |
2,770
-46
| -2% | -$4.02K | 0.12% | 160 |
|
|
2022
Q4 | $255K | Sell |
2,816
-325
| -10% | -$27.4K | 0.13% | 155 |
|
|
2022
Q3 | $239K | Sell |
3,141
-152
| -5% | -$12.6K | 0.14% | 150 |
|
|
2022
Q2 | $278K | Sell |
3,293
-125
| -4% | -$11K | 0.15% | 138 |
|
|
2022
Q1 | $300K | Hold |
3,418
| – | – | 0.15% | 145 |
|
|
2021
Q4 | $299K | Sell |
3,418
-9
| -0.3% | -$747 | 0.14% | 144 |
|
|
2021
Q3 | $280K | Buy |
3,427
+9
| +0.3% | +$810 | 0.15% | 131 |
|
|
2021
Q2 | $312K | Sell |
3,418
-100
| -3% | -$8.9K | 0.18% | 124 |
|
|
2021
Q1 | $301K | Hold |
3,518
| – | – | 0.19% | 115 |
|
|
2020
Q4 | $332K | Buy |
3,518
+160
| +5% | +$14K | 0.24% | 104 |
|
|
2020
Q3 | $292K | Sell |
3,358
-625
| -16% | -$54.1K | 0.25% | 94 |
|
|
2020
Q2 | $348K | Buy |
3,983
+15
| +0.4% | +$1.29K | 0.33% | 84 |
|
|
2020
Q1 | $327K | Sell |
3,968
-37
| -0.9% | -$3.3K | 0.37% | 74 |
|
|
2019
Q4 | $379K | Sell |
4,005
-75
| -2% | -$6.73K | 0.3% | 85 |
|
|
2019
Q3 | $355K | Sell |
4,080
-50
| -1% | -$4.49K | 0.31% | 82 |
|
|
2019
Q2 | $377K | Sell |
4,130
-680
| -14% | -$57.6K | 0.34% | 79 |
|
|
2019
Q1 | $414K | Sell |
4,810
-167
| -3% | -$13.4K | 0.39% | 75 |
|
|
2018
Q4 | $383K | Sell |
4,977
-335
| -6% | -$26.1K | 0.4% | 74 |
|
|
2018
Q3 | $410K | Sell |
5,312
-2,790
| -34% | -$206K | 0.35% | 77 |
|
|
2018
Q2 | $548K | Sell |
8,102
-195
| -2% | -$13.5K | 0.48% | 65 |
|
|
2018
Q1 | $601K | Buy |
8,297
+1,947
| +31% | +$148K | 0.52% | 63 |
|
|
2017
Q4 | $478K | Buy |
+6,350
| New | +$479K | 0.42% | 71 |
|
Other funds holding NVS
Kendall Capital Management's NVS Position: Q1 2026 in Review
Kendall Capital Management held its Novartis (NVS) position steady in Q1 2026 at 2,295 shares worth $351K. The position accounts for 0.07% of the portfolio, ranked #180.
Kendall Capital Management first reported a position in NVS in Q4 2017 and has held it in 34 quarters since. The position peaked at $601K in Q1 2018. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Kendall Capital Management held 2,295 shares of Novartis worth $351K as of Q1 2026.
- Kendall Capital Management left its Novartis share count unchanged in Q1 2026.
- Novartis made up 0.07% of Kendall Capital Management's portfolio in Q1 2026, its #180 holding.
- Kendall Capital Management first reported a position in Novartis in Q4 2017 and has held it in 34 quarters since.
- Kendall Capital Management's Novartis position peaked at $601K in Q1 2018.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Kendall Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.